Metabolismo de los estrógenos endógenos y cáncer de mama
Palabras clave:
CÁNCER DE MAMA, ESTRÓGENOS, DIETAResumen
El cáncer de mama es el cáncer más frecuente en las mujeres de los países desarrollados occidentales. Si bien Uruguay no integra este grupo de países, el cáncer de mama presenta cifras similares a estos, con tasas de incidencia y mortalidad extremadamente altas. La tasa de mortalidad ajustada por edad, en el período de 1993 a 1997, en Uruguay es de 25,1 cada 100.000 mujeres por año, una de las más altas a nivel mundial. Esto ha llevado a que el cáncer de mama sea un grave problema de salud pública en nuestro país.
La relación del cáncer de mama con el uso de hormonoterapia de reemplazo está firmemente establecida. Diversos estudios, en especial el estudio WHI (Women’s Health Initiative), han confirmado el mayor riesgo con el aporte exógeno de estrógenos. Esto, junto a los mayores riesgos cardiovasculares de la terapia estrogénica para los trastornos climatéricos, ha llevado a la drástica reducción de sus indicaciones y uso a nivel mundial.
Sin embargo, el rol de estas hormonas en la patogénesis del cáncer de mama no se reduce a su administración exógena. Los estrógenos endógenos tienen un papel preponderante en la génesis de este cáncer, y distintas situaciones dependientes del ambiente y los hábitos de vida pueden modificar el riesgo de cáncer de mama mediado por estrógenos endógenos. El presente artículo realiza una revisión sobre el metabolismo de los estrógenos y su relación con el cáncer de mama, dado que los distintos metabolitos de los estrógenos tienen acciones biológicas diferentes y una incidencia opuesta en el riesgo de este cáncer. La ruta de metabolización hacia la 2-alfa hydroxyestrona se asocia a una reducción de 40% de desarrollar cáncer de mama. Se analiza la influencia de los cambios dietéticos en la ruta de metabolización de los estrógenos y se plantea la hipótesis de aplicar el cambio de la dieta como una de las estrategias para abatir la incidencia del cáncer de mama.
Citas
1) Barrios E, Ronco A, Fierro L, De-Stéfani E, Vassallo J. Tendencias de la mortalidad por cáncer en Uruguay 1953-1997. Rev Med Uruguay 2002; 18: 167-74.
2) Ministerio de Salud Pública (Uruguay). División Estadística. Mortalidad clasificada por causa, sexo y edad. Montevideo. Montevideo: MSP, 1998.
3) De-Stéfani E, Fierro L, Barrios E, Ronco A. Cancer Mortality Trends in Uruguay, 1953-91. Int J Cancer 1994; 56(5): 634-9.
4) Writing Group for the Woman Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Woman. Principal results from the Women´s Health Initiative Randomized Controlled Trial. JAMA 2002; 288(3): 321-33.
5) Million Women Study Collborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 2(362): 419-27.
6) Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative re analysis of data from 51 epidemiological studies of 52.705 women with breast cancer and 108.411 women without breast cancer. Lancet 1997; 350(9084): 1047-59.
7) International Agency for Research on Cancer. Sex hormones (II). In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. 1976 Vol 21. Lyon, France. Last updated: 6 April 1998. Obtenido de: http://monographs.iarc.fr/htdocs/indexes/vol21index.html. Fecha acceso: septiembre de 2004.
8) Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001; 344(23): 276-85.
9) Fuchs-Young R, Glasebrook AL, Short LL, Draper MW, Rippy MK, Cole HW, et al. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci 1995; 761: 355-60.
10) Russo J, Lareef MH, Tahin Q, Hu YF, Slater C, Ao X, et al. 17 Beta-estradiol is carcinogenic in human breast epithelial cells. J Steroid Biochem Mol Biol 2002; 80(2): 149-62.
11) Liehr JG. Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. Hum Reprod Update 2001; 7(3): 273-81.
12) Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994; 15: 342-55.
13) Dunn LJ, Bradbury JT. Endocrine factors in endometrial carcinoma: a preliminary report. Am J Obstet Gynecol 1967; 97: 465-71.
14) Ackerman GE, Smith ME, Mendelson CR, MacDonald PC, Simpson ER. Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J Clin Endocrinol Metab 1981; 53: 412-7.
15) Simpson ER, Rubin G, Clyne C, Robertson K, O’Donnell, L, Jones M, et al. The role of local estrogen biosynthesis in males and females. Trends Endocrinol Metab 2000; 11: 184-8.
16) Bulun SE, Simpson ER, Word RA. Expression of the CYP19 gene and its product aromatase cytochrome P450 in human leiomyoma tissues and cells in culture. J Clin Endocrinol Metab 1994; 78: 736-43.
17) Noble LS, Simpson ER, Johns A, Bulun SE. Aromatase expression inendometriosis. J Clin Endocrinol Metab 1996; 81: 174-9.
18) Bulun SE, Price TM, Mahendroo MS, Aitken J, Simpson ER. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 1993; 77: 1622-8.
19) Yue W, Wang JP, Hamilton CJ, Demers LM, Santen RJ. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 1998; 58: 927-32.
20) Haynes GJ, Dowsett AG, Lonning PE. Influence of letrozole (Femera) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized cross-over study. J Clin Oncol 2002; 20: 751-7.
21) Bajetta E, Zilembo N, Bichisao E, Martinetti A, Buzzoni R, Pozzi P, et al. Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors. Ann Oncol 2000; 11: 1017-22.
22) Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with petrozole and norethindrone acetate: a pilot study. Fertil Steril 2004; 81(2): 290-6.
23) Shozu M, Murakami K, Segawa T, Kasai T, Inoue M. Successful treatment of symptomatic uterine leiomyoma with a non-steroidal aromatase inhibitor in a perimenopausal woman. Fertil Steril 2003; 79: 628-31.
24) Ellis MJ, Jaenicke F, Llombart-Cussac L. A randomized double-blind multicentre study of preoperative tamoxifen versus Femara (letrozole) for postmenopausal women with ER and/or PgR positive breast cancer ineligible for breast conserving surgery -correlation of clinical response with tumour gene expression and proliferation. Breast Cancer Res Treat 2000; 64: 29.
25) Fishman J, Bradlow HL, Schneider J, Anderson KE, Kappas A. Radiometric analysis of biological oxidations in man: sex differences in estradiol metabolism. Proc Natl Acad Sci 1980; 77: 4957-60.
26) Fishman J, Osborne MP, Telang NT. The role of estrogen in mammary carcinogenesis. Ann NY Acad Sci 1995; 768: 91-100.
27) Hulka BS, Stark AT. Breast cancer: cause and prevention. Lancet 1995; 346(8979): 883-7.
28) Kreiger N, Sloan M, Cotterchis M, Kirch V. The risk of breast cancer following reproductive surgery. Eur J Cancer 1999; 35: 97-101.
29) Broocks A, Pirke KM, Schweiger U, Tuschl RJ, Laessle RG, Strowitzki T, et al. Cyclic ovarian function in recreational athletes. J Appl Physiol 1990; (68): 2083-6.
30) Bullen BA, Skrinar GS, Beitins IZ, Von Mering G, Turnbull BA, McArthur JW. Induction of menstrual disorders by strenuous exercise in untrained women. N Engl J Med 1985; 312(21): 1349-53.
31) Feicht CB, Johnson TS, Martin BJ, Sparkes KE, Wagner WJr. Secondary amenorrhea in athletes. Lancet 1978; 2(8100): 1145-6.
32) Bernstein L, Henderson BE, Hanisch R, Sullivan-Halley J, Ross RK. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 1994; 86(18): 1403-8.
33) Thune I, Brenn T, Lunde E, Gaard M. Physical activity and the risk of breast cancer. N Engl J Med 1997; 336(18): 1269-75.
34) Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896; 2: 104-7.
35) Thomas HV, Reeves GK, Key TJ. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997; 8: 922-8.
36) Feigelson HS, Ross RK, Yu MC, Coetzee GA, Reichardt JK, Henderson BE. Genetic susceptibility to cancer from exogenous and endogenous exposures. J Cell Biochem Suppl 1996; 25: 15-22.
37) Sager R. Tumor-suppressor genes: The puzzle and the promise. Science 1989; 246(4936): 1406-12.
38) Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Hershmann K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266(5182): 66-71.
39) Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378(6559): 789-92.
40) Bradlow HL. Nutrient modulation of female hormone metabolism: Modifying breast cancer risk. In: Functional Medicine Approaches to Endocrine Disturbances of Aging. Vancouver: British Columbia: Institute of Functional Medicine Proceedings, 2001: 100-14.
41) Bolton JL, Pisha E, Zhang F, Qiu S. Role of quinoids in estrogen carcinogenesis. Chem Res Toxicol 1998; 11(10): 1113-27.
42) Kabat GC, Chang CJ, Sparano JA, Sepkovie DW, Hu XP, Khalil A, et al. Urinary estrogen metabolitos and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997; 6(7): 505-9.
43) Davis DL, Telang NT, Osborne MP, Bradlow HL. Medical hypothesis: bifunctional genetic hormonal pathways to breast cancer. Environ Health Perspect 1997; 105: 571-6.
44) Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16 alphahydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 1988; 85: 7831-5.
45) Lustig R, Kendrick-Parker C, Jordan V. Effects of 16a-hydroxyestrone on MCF-7 cell proliferation and estrogen receptor regulation in vitro. Endocr Soc Proc 1994; 75: 317-20.
46) Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998; 78: 1250-5.
47) Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alphahydroxy-estrone ratio in premenopausal and postmenopausal women. Epidemiology 2000; 11: 635-40.
48) Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA 1982; 79: 3047-51.
49) Messina MJ. Legumes and soybeans: overview of their nutritional profiles and health effects. Am J Clin Nutr 1999; 70(3 Suppl): 439S-450S.
50) Barnes S. Phytoestrogens and cancer. Baillières Clin Endocrinol Metab 1998; 12: 559-79.
51) Lamartiniere CA. Protection against breast cancer with genistein: a component of soy. Am J Clin Nutr 2000; 71(6 Suppl): 1705S-1707S.
52) Adlercreutz H. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest 1990; 201: 3-21.
53) Dai Q, Shu X-O, Jin F, Potter JD, Kushi LH, Teas J, et al. Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. Br J Cancer 2001; 85: 372-87.
54) Wu AH, Ziegler RG, Nomura AMY, West DW, Kolonel LN, Horn-Ross PL, et al. Soy intake and risk of breast cancer in Asians and Asian Americans. Am J Clin Nutr 1998; 68(6 Suppl): 1437S-1443S.
55) Hadfield P. Japanese swallow Western diseases. New Scientist 1995; 2: 5-7.
56) Bernstein L, Yuan JM, Ross RK, Pike MC, Hanisch R, Lobo R, et al. Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results form two breast cancer case-control studies. Cancer Causes Control 1990; 1(1): 51-8.
57) MacMahon B, Cole P, Brown JB, Lin TM, Morgan RW, Woo NC. Urine oestrogen profiles of Asian and North American women. Int J Cancer 1974; 14(2): 161-7.
58) Chang YC, Riby J, Chang GH, Peng BC, Firestone G, Bjeldames LF. Cytostatic and antiestrogenic effects of 2-(indol-3-ylmethyl)-3,3'- diindolylmethane, a major in vivo product of dietary indole-3-carbinol. Biochem Pharmacol 1999; 58(5): 825-34.
59) Mori M, Tominaga T, Tamaoki BI. Steroid metabolism in normal mammary gland and in the dimethylbenzanthracene-induced mammary tumor of rats. Endocrinology. 1978; 102: 1387-97.
60) Bradlow HL, Sepkovic DW, Telang NT, Osborne MP. Indole-3-carbinol. A novel approach to breast cancer prevention. Ann N Y Acad Sci 1995; 768: 180-200.
61) Bradfield CA, Bjeldanes LF. Structure-activity relationships of dietary indoles: a proposed mechanism of action as modifiers of xenobiotic metabolism. J Toxicol Environ Health 1987; 21: 311-23.
62) Michnovicz JJ, Bradlow HL. Induction of estradiol metabolism by dietary indole-3- carbinol in humans. J Natl Cancer Inst 1990; 82: 947-9.
63) Bradlow HL, Sepkovic DW, Telang NT, Osborne MP. Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent. Ann NY Acad Sci 1999; 889: 204-13.
64) Wong GY, Bradlow L, Sepkovic D, Mehl S, Mailman J, Osborne MP. Dose-ranging study of indole-3-carbinol for breast cancer prevention. J Cell Biochem Suppl 1997; 29: 111-6.
65) Cover CM, Hsieh SJ, Cram EJ, Hong C, Riby JE, Bjeldanes LF, et al. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 1999; 59: 1244-51.
66) Michnovicz JJ. Increased estrogen 2-hydroxylation in obese women using oral indole-3-carbinol. Int J Obes Relat Metab Disord 1998; 22: 227-9.
67) Terry P, Wolk A, Persson I, Magnusson C. Brassica vegetables and breast cancer risk. JAMA 2001; 285: 2975-7.
68) Michnovicz JJ, Naganuma H, Hershcopf RJ, Bradlow HL, Fishman J. Increased urinary catechol estrogen excretion in female smokers. Steroids 1988; 52: 69-83.
69) Taioli E, Bradlow HL, Garbers SV, Sepkovic DW, Osborne MP, Trachman J, et al. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect 1999; 23: 232-7.
70) Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-hydroxyestrone: the ‘good’ estrogen. J Endocrinol 1996; 150 Suppl: S259-S265.
71) Xu X, Duncan AM, Merz BE, Kurzer MS. Effects of soy isoflavones on estrogen and phytoestrogen metabolism in premenopausal women. Cancer Epidemiol Biomarkers Prev 1998; 7(12): 1101-8.
72) Xu X, Duncan AM, Wangen KE, Kurzer MS. Soy consumption alters endogenous estrogen metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2000; 9(8): 781-6.
73) Lu LJ, Anderson KE, Grady JJ, Nagamani M. Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. Cancer Epidemiol Biomarkers Prev 1996; 5: 63-70.
74) Burow ME, Boue SM, Collins-Burow BM, Melnik LI, Duong BN, Carter-Wientjes CH, et al. Phytochemical glyceollins, isolated from soy, mediate hormonal effects through estrogen receptor á and â. J Clin Endocrinol Metab 2001; 86: 1750-8.
75) Morito K, Aomori T, Hirose T, Kinjo J, Hasegawa J, Ogawa S, et al. Interaction of phytoestrogens with estrogen receptors á and â (II). Biol Pharm Bull 2002; 25: 48-52.
76) An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, Leitman DC. Estrogen receptor â-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 2001; 276: 17808-14.
77) Liu J, Burdette JE, Xu H, Gu C, van Breemen RB, Bhat KPL, et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem 2001; 49: 2472-9.
78) Fioravanti L, Cappelletti V, Miodini P, Ronchi E, Brivio M, Di Fronzo G. Genistein in the control of breast cancer cell growth: insights into the mechanism of action in vitro. Cancer Lett 1998; 130: 143-52.
79) Frairia R, Fortunati N, Fazzari A, Fissore F, Comba A, Becchis M, et al. Sex steroid binding protein is a negative modulator of estrogen-induced breast cancer cell growth. Ann NY Acad Sci 1996; 784: 362-9.
80) Martin ME, Haourigui M, Pelissero C, Benassayag C, Nunez EA. Interactions between phytoestrogens and human sex steroid binding protein. Life Sci 1996; 58: 429-36.
81) Grube BJ, Eng ET, Kao Y-C, Kwon A, Chen S. White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. J Nutr 2001; 131: 3288-93.
82) Leung LK, Wang TT. BCL-2 is not reduced in the death of MCF-7 cells at low genistein concentration. J Nutr 2000; 130: 2922-6.
83) Pozo-Guisado E, Álvarez-Barrientos A, Mulero-Navarro S, Santiago- Josefat B, Fernández-Salguero PM. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alterations of the cell cycle. Biochem Pharmacol 2002; 64: 1375-86.
84) Tanos V, Brzezinski A, Drize O, Strauss N, Peretz T. Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. Eur J Obstet Gynecol Reprod Biol 2002; 102: 188-94.
85) Key TJ, Sharp GB, Appleby PN, Beral V, Goodman MT, Soda M, et al. Soya foods and breast cancer risk: a prospective study in Hiroshima and Nagasaki, Japan. Br J Cancer 1999; 81: 1248-56.
86) Trock BJ, White BL, Clarke R, Hilakivi-Clarke L. Meta-analysis of soy intake and breast cancer risk. J Nutr 2000; 130: 653S–680S.
87) Franke AA, Custer LJ, Tanaka Y. Isoflavones in human breast milk and other biological fluids. Am J Clin Nutr 1998Dic; 68(6 Suppl): 1466S-1473S.
88) Lamartiniere CA. Timing of exposure and mammary cancer risk. J Mammary Gland Biol Neoplasia 2002; 7(1):67-76.
89) Mousavi Y, Adlercreutz H. Enterolactone and estradiol inhibit each other’s proliferative effect on MCF-7 breast cancer cells in culture. J Steroid Biochem Mol Biol Mar 1992; 41(3-8): 615-9.
90) Haggans CJ, Hutchins AM, Olson BA, Thomas W, Martini MC, Slavin JL. Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women. Nutr Cancer 1999; 33(2): 188-95.
91) Haggans CJ, Travelli EJ, Thomas W, Martini MC, Slavin JL. The effect of flaxseed and wheat bran consumption on urinary estrogen metabolites in premenopausal women. Cancer Epidemiol Biomarkers Prev 2000; 9: 719-25.
92) Spierto FW, Gardner F, Smith SJ. Evaluation of an EIA method for measuring serum levels of the estrogen metabolite 2-hydroxyestrone in adults. Steroids 2001; 66: 59-62.
93) Ziegler RG, Rossi SC, Fears TR, Bradlow HL, Adlercreutz H, Sepkovic D, et al. Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine. Environ Health Perspect 1997; 105: 607-14.
94) Kabat GC, Chang CJ, Sparano JA, Sepkovie DW, Hu XP, Khalil A, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997; 6: 505-9.
2) Ministerio de Salud Pública (Uruguay). División Estadística. Mortalidad clasificada por causa, sexo y edad. Montevideo. Montevideo: MSP, 1998.
3) De-Stéfani E, Fierro L, Barrios E, Ronco A. Cancer Mortality Trends in Uruguay, 1953-91. Int J Cancer 1994; 56(5): 634-9.
4) Writing Group for the Woman Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Woman. Principal results from the Women´s Health Initiative Randomized Controlled Trial. JAMA 2002; 288(3): 321-33.
5) Million Women Study Collborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 2(362): 419-27.
6) Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative re analysis of data from 51 epidemiological studies of 52.705 women with breast cancer and 108.411 women without breast cancer. Lancet 1997; 350(9084): 1047-59.
7) International Agency for Research on Cancer. Sex hormones (II). In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. 1976 Vol 21. Lyon, France. Last updated: 6 April 1998. Obtenido de: http://monographs.iarc.fr/htdocs/indexes/vol21index.html. Fecha acceso: septiembre de 2004.
8) Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001; 344(23): 276-85.
9) Fuchs-Young R, Glasebrook AL, Short LL, Draper MW, Rippy MK, Cole HW, et al. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci 1995; 761: 355-60.
10) Russo J, Lareef MH, Tahin Q, Hu YF, Slater C, Ao X, et al. 17 Beta-estradiol is carcinogenic in human breast epithelial cells. J Steroid Biochem Mol Biol 2002; 80(2): 149-62.
11) Liehr JG. Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. Hum Reprod Update 2001; 7(3): 273-81.
12) Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994; 15: 342-55.
13) Dunn LJ, Bradbury JT. Endocrine factors in endometrial carcinoma: a preliminary report. Am J Obstet Gynecol 1967; 97: 465-71.
14) Ackerman GE, Smith ME, Mendelson CR, MacDonald PC, Simpson ER. Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J Clin Endocrinol Metab 1981; 53: 412-7.
15) Simpson ER, Rubin G, Clyne C, Robertson K, O’Donnell, L, Jones M, et al. The role of local estrogen biosynthesis in males and females. Trends Endocrinol Metab 2000; 11: 184-8.
16) Bulun SE, Simpson ER, Word RA. Expression of the CYP19 gene and its product aromatase cytochrome P450 in human leiomyoma tissues and cells in culture. J Clin Endocrinol Metab 1994; 78: 736-43.
17) Noble LS, Simpson ER, Johns A, Bulun SE. Aromatase expression inendometriosis. J Clin Endocrinol Metab 1996; 81: 174-9.
18) Bulun SE, Price TM, Mahendroo MS, Aitken J, Simpson ER. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 1993; 77: 1622-8.
19) Yue W, Wang JP, Hamilton CJ, Demers LM, Santen RJ. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 1998; 58: 927-32.
20) Haynes GJ, Dowsett AG, Lonning PE. Influence of letrozole (Femera) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized cross-over study. J Clin Oncol 2002; 20: 751-7.
21) Bajetta E, Zilembo N, Bichisao E, Martinetti A, Buzzoni R, Pozzi P, et al. Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors. Ann Oncol 2000; 11: 1017-22.
22) Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with petrozole and norethindrone acetate: a pilot study. Fertil Steril 2004; 81(2): 290-6.
23) Shozu M, Murakami K, Segawa T, Kasai T, Inoue M. Successful treatment of symptomatic uterine leiomyoma with a non-steroidal aromatase inhibitor in a perimenopausal woman. Fertil Steril 2003; 79: 628-31.
24) Ellis MJ, Jaenicke F, Llombart-Cussac L. A randomized double-blind multicentre study of preoperative tamoxifen versus Femara (letrozole) for postmenopausal women with ER and/or PgR positive breast cancer ineligible for breast conserving surgery -correlation of clinical response with tumour gene expression and proliferation. Breast Cancer Res Treat 2000; 64: 29.
25) Fishman J, Bradlow HL, Schneider J, Anderson KE, Kappas A. Radiometric analysis of biological oxidations in man: sex differences in estradiol metabolism. Proc Natl Acad Sci 1980; 77: 4957-60.
26) Fishman J, Osborne MP, Telang NT. The role of estrogen in mammary carcinogenesis. Ann NY Acad Sci 1995; 768: 91-100.
27) Hulka BS, Stark AT. Breast cancer: cause and prevention. Lancet 1995; 346(8979): 883-7.
28) Kreiger N, Sloan M, Cotterchis M, Kirch V. The risk of breast cancer following reproductive surgery. Eur J Cancer 1999; 35: 97-101.
29) Broocks A, Pirke KM, Schweiger U, Tuschl RJ, Laessle RG, Strowitzki T, et al. Cyclic ovarian function in recreational athletes. J Appl Physiol 1990; (68): 2083-6.
30) Bullen BA, Skrinar GS, Beitins IZ, Von Mering G, Turnbull BA, McArthur JW. Induction of menstrual disorders by strenuous exercise in untrained women. N Engl J Med 1985; 312(21): 1349-53.
31) Feicht CB, Johnson TS, Martin BJ, Sparkes KE, Wagner WJr. Secondary amenorrhea in athletes. Lancet 1978; 2(8100): 1145-6.
32) Bernstein L, Henderson BE, Hanisch R, Sullivan-Halley J, Ross RK. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 1994; 86(18): 1403-8.
33) Thune I, Brenn T, Lunde E, Gaard M. Physical activity and the risk of breast cancer. N Engl J Med 1997; 336(18): 1269-75.
34) Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896; 2: 104-7.
35) Thomas HV, Reeves GK, Key TJ. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997; 8: 922-8.
36) Feigelson HS, Ross RK, Yu MC, Coetzee GA, Reichardt JK, Henderson BE. Genetic susceptibility to cancer from exogenous and endogenous exposures. J Cell Biochem Suppl 1996; 25: 15-22.
37) Sager R. Tumor-suppressor genes: The puzzle and the promise. Science 1989; 246(4936): 1406-12.
38) Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Hershmann K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266(5182): 66-71.
39) Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378(6559): 789-92.
40) Bradlow HL. Nutrient modulation of female hormone metabolism: Modifying breast cancer risk. In: Functional Medicine Approaches to Endocrine Disturbances of Aging. Vancouver: British Columbia: Institute of Functional Medicine Proceedings, 2001: 100-14.
41) Bolton JL, Pisha E, Zhang F, Qiu S. Role of quinoids in estrogen carcinogenesis. Chem Res Toxicol 1998; 11(10): 1113-27.
42) Kabat GC, Chang CJ, Sparano JA, Sepkovie DW, Hu XP, Khalil A, et al. Urinary estrogen metabolitos and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997; 6(7): 505-9.
43) Davis DL, Telang NT, Osborne MP, Bradlow HL. Medical hypothesis: bifunctional genetic hormonal pathways to breast cancer. Environ Health Perspect 1997; 105: 571-6.
44) Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16 alphahydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 1988; 85: 7831-5.
45) Lustig R, Kendrick-Parker C, Jordan V. Effects of 16a-hydroxyestrone on MCF-7 cell proliferation and estrogen receptor regulation in vitro. Endocr Soc Proc 1994; 75: 317-20.
46) Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998; 78: 1250-5.
47) Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alphahydroxy-estrone ratio in premenopausal and postmenopausal women. Epidemiology 2000; 11: 635-40.
48) Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA 1982; 79: 3047-51.
49) Messina MJ. Legumes and soybeans: overview of their nutritional profiles and health effects. Am J Clin Nutr 1999; 70(3 Suppl): 439S-450S.
50) Barnes S. Phytoestrogens and cancer. Baillières Clin Endocrinol Metab 1998; 12: 559-79.
51) Lamartiniere CA. Protection against breast cancer with genistein: a component of soy. Am J Clin Nutr 2000; 71(6 Suppl): 1705S-1707S.
52) Adlercreutz H. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest 1990; 201: 3-21.
53) Dai Q, Shu X-O, Jin F, Potter JD, Kushi LH, Teas J, et al. Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. Br J Cancer 2001; 85: 372-87.
54) Wu AH, Ziegler RG, Nomura AMY, West DW, Kolonel LN, Horn-Ross PL, et al. Soy intake and risk of breast cancer in Asians and Asian Americans. Am J Clin Nutr 1998; 68(6 Suppl): 1437S-1443S.
55) Hadfield P. Japanese swallow Western diseases. New Scientist 1995; 2: 5-7.
56) Bernstein L, Yuan JM, Ross RK, Pike MC, Hanisch R, Lobo R, et al. Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results form two breast cancer case-control studies. Cancer Causes Control 1990; 1(1): 51-8.
57) MacMahon B, Cole P, Brown JB, Lin TM, Morgan RW, Woo NC. Urine oestrogen profiles of Asian and North American women. Int J Cancer 1974; 14(2): 161-7.
58) Chang YC, Riby J, Chang GH, Peng BC, Firestone G, Bjeldames LF. Cytostatic and antiestrogenic effects of 2-(indol-3-ylmethyl)-3,3'- diindolylmethane, a major in vivo product of dietary indole-3-carbinol. Biochem Pharmacol 1999; 58(5): 825-34.
59) Mori M, Tominaga T, Tamaoki BI. Steroid metabolism in normal mammary gland and in the dimethylbenzanthracene-induced mammary tumor of rats. Endocrinology. 1978; 102: 1387-97.
60) Bradlow HL, Sepkovic DW, Telang NT, Osborne MP. Indole-3-carbinol. A novel approach to breast cancer prevention. Ann N Y Acad Sci 1995; 768: 180-200.
61) Bradfield CA, Bjeldanes LF. Structure-activity relationships of dietary indoles: a proposed mechanism of action as modifiers of xenobiotic metabolism. J Toxicol Environ Health 1987; 21: 311-23.
62) Michnovicz JJ, Bradlow HL. Induction of estradiol metabolism by dietary indole-3- carbinol in humans. J Natl Cancer Inst 1990; 82: 947-9.
63) Bradlow HL, Sepkovic DW, Telang NT, Osborne MP. Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent. Ann NY Acad Sci 1999; 889: 204-13.
64) Wong GY, Bradlow L, Sepkovic D, Mehl S, Mailman J, Osborne MP. Dose-ranging study of indole-3-carbinol for breast cancer prevention. J Cell Biochem Suppl 1997; 29: 111-6.
65) Cover CM, Hsieh SJ, Cram EJ, Hong C, Riby JE, Bjeldanes LF, et al. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 1999; 59: 1244-51.
66) Michnovicz JJ. Increased estrogen 2-hydroxylation in obese women using oral indole-3-carbinol. Int J Obes Relat Metab Disord 1998; 22: 227-9.
67) Terry P, Wolk A, Persson I, Magnusson C. Brassica vegetables and breast cancer risk. JAMA 2001; 285: 2975-7.
68) Michnovicz JJ, Naganuma H, Hershcopf RJ, Bradlow HL, Fishman J. Increased urinary catechol estrogen excretion in female smokers. Steroids 1988; 52: 69-83.
69) Taioli E, Bradlow HL, Garbers SV, Sepkovic DW, Osborne MP, Trachman J, et al. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect 1999; 23: 232-7.
70) Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-hydroxyestrone: the ‘good’ estrogen. J Endocrinol 1996; 150 Suppl: S259-S265.
71) Xu X, Duncan AM, Merz BE, Kurzer MS. Effects of soy isoflavones on estrogen and phytoestrogen metabolism in premenopausal women. Cancer Epidemiol Biomarkers Prev 1998; 7(12): 1101-8.
72) Xu X, Duncan AM, Wangen KE, Kurzer MS. Soy consumption alters endogenous estrogen metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2000; 9(8): 781-6.
73) Lu LJ, Anderson KE, Grady JJ, Nagamani M. Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. Cancer Epidemiol Biomarkers Prev 1996; 5: 63-70.
74) Burow ME, Boue SM, Collins-Burow BM, Melnik LI, Duong BN, Carter-Wientjes CH, et al. Phytochemical glyceollins, isolated from soy, mediate hormonal effects through estrogen receptor á and â. J Clin Endocrinol Metab 2001; 86: 1750-8.
75) Morito K, Aomori T, Hirose T, Kinjo J, Hasegawa J, Ogawa S, et al. Interaction of phytoestrogens with estrogen receptors á and â (II). Biol Pharm Bull 2002; 25: 48-52.
76) An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, Leitman DC. Estrogen receptor â-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 2001; 276: 17808-14.
77) Liu J, Burdette JE, Xu H, Gu C, van Breemen RB, Bhat KPL, et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem 2001; 49: 2472-9.
78) Fioravanti L, Cappelletti V, Miodini P, Ronchi E, Brivio M, Di Fronzo G. Genistein in the control of breast cancer cell growth: insights into the mechanism of action in vitro. Cancer Lett 1998; 130: 143-52.
79) Frairia R, Fortunati N, Fazzari A, Fissore F, Comba A, Becchis M, et al. Sex steroid binding protein is a negative modulator of estrogen-induced breast cancer cell growth. Ann NY Acad Sci 1996; 784: 362-9.
80) Martin ME, Haourigui M, Pelissero C, Benassayag C, Nunez EA. Interactions between phytoestrogens and human sex steroid binding protein. Life Sci 1996; 58: 429-36.
81) Grube BJ, Eng ET, Kao Y-C, Kwon A, Chen S. White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. J Nutr 2001; 131: 3288-93.
82) Leung LK, Wang TT. BCL-2 is not reduced in the death of MCF-7 cells at low genistein concentration. J Nutr 2000; 130: 2922-6.
83) Pozo-Guisado E, Álvarez-Barrientos A, Mulero-Navarro S, Santiago- Josefat B, Fernández-Salguero PM. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alterations of the cell cycle. Biochem Pharmacol 2002; 64: 1375-86.
84) Tanos V, Brzezinski A, Drize O, Strauss N, Peretz T. Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. Eur J Obstet Gynecol Reprod Biol 2002; 102: 188-94.
85) Key TJ, Sharp GB, Appleby PN, Beral V, Goodman MT, Soda M, et al. Soya foods and breast cancer risk: a prospective study in Hiroshima and Nagasaki, Japan. Br J Cancer 1999; 81: 1248-56.
86) Trock BJ, White BL, Clarke R, Hilakivi-Clarke L. Meta-analysis of soy intake and breast cancer risk. J Nutr 2000; 130: 653S–680S.
87) Franke AA, Custer LJ, Tanaka Y. Isoflavones in human breast milk and other biological fluids. Am J Clin Nutr 1998Dic; 68(6 Suppl): 1466S-1473S.
88) Lamartiniere CA. Timing of exposure and mammary cancer risk. J Mammary Gland Biol Neoplasia 2002; 7(1):67-76.
89) Mousavi Y, Adlercreutz H. Enterolactone and estradiol inhibit each other’s proliferative effect on MCF-7 breast cancer cells in culture. J Steroid Biochem Mol Biol Mar 1992; 41(3-8): 615-9.
90) Haggans CJ, Hutchins AM, Olson BA, Thomas W, Martini MC, Slavin JL. Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women. Nutr Cancer 1999; 33(2): 188-95.
91) Haggans CJ, Travelli EJ, Thomas W, Martini MC, Slavin JL. The effect of flaxseed and wheat bran consumption on urinary estrogen metabolites in premenopausal women. Cancer Epidemiol Biomarkers Prev 2000; 9: 719-25.
92) Spierto FW, Gardner F, Smith SJ. Evaluation of an EIA method for measuring serum levels of the estrogen metabolite 2-hydroxyestrone in adults. Steroids 2001; 66: 59-62.
93) Ziegler RG, Rossi SC, Fears TR, Bradlow HL, Adlercreutz H, Sepkovic D, et al. Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine. Environ Health Perspect 1997; 105: 607-14.
94) Kabat GC, Chang CJ, Sparano JA, Sepkovie DW, Hu XP, Khalil A, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997; 6: 505-9.
Descargas
Publicado
2005-03-31
Cómo citar
1.
Cóppola F, Nader J, Aguirre R. Metabolismo de los estrógenos endógenos y cáncer de mama. Rev. Méd. Urug. [Internet]. 31 de marzo de 2005 [citado 22 de noviembre de 2024];21(1):15-22. Disponible en: https://revista.rmu.org.uy/index.php/rmu/article/view/823
Número
Sección
Trabajos de Revisión o Actualización y Puestas al día
